Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker URGN · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Oct 22, 2026 | A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle In… NCT06331299 · Bladder Cancer, Urothelial Carcinoma UGN-103 | URGN UroGen Pharma Ltd. | Phase 3 | Completed | 99 | Sep 11, 2025 | Registry ↗ |
| Sep 29, 2026 | uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated W… NCT05874921 · Urothelial Carcinoma, Urothelial Carcinoma Recurrent Jelmyto (mitomycin) for pyelocalyceal solution | URGN UroGen Pharma Ltd. | — | Recruiting | 450 | Oct 2027 | Registry ↗ |
| Sep 15, 2026 | Named Patient Program for Mitomycin for Pyelocalyceal Solution NCT05494411 · Urothelial Cancer of Renal Pelvis, Urothelial Carcinoma of… Mitomycin for pyelocalyceal solution | URGN UroGen Pharma Ltd. | — | Available | — | — | Registry ↗ |
| Sep 3, 2026 | A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer NCT06774131 · Upper Urinary Tract Urothelial Carcinoma, Urothelial Carcin… UGN-104 | URGN UroGen Pharma Ltd. | Phase 3 | Recruiting | 70 | Mar 2027 | Registry ↗ |
| May 11, 2026 | A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invas… NCT05243550 · Bladder Cancer, Urothelial Carcinoma UGN-102 | URGN UroGen Pharma Ltd. | Phase 3 | Active, not recruiting | 240 | Apr 26, 2023 | Registry ↗ |
| Jan 14, 2026 | A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder C… NCT05375903 · Non-muscle Invasive Bladder Cancer, NMIBC UGN-301, UGN-201 | URGN UroGen Pharma Ltd. | Phase 1 | Completed | 51 | Jan 9, 2026 | Registry ↗ |
| Sep 19, 2024 | Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bla… NCT05136898 · Bladder Cancer, Urothelial Carcinoma UGN-102 | URGN UroGen Pharma Ltd. | Phase 3 | Completed | 8 | Feb 2, 2023 | Registry ↗ |
| Jun 6, 2024 | A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer NCT04688931 · Bladder Cancer, Urothelial Carcinoma UGN-102, TURBT | URGN UroGen Pharma Ltd. | Phase 3 | Terminated | 282 | Mar 17, 2023 | Registry ↗ |
| Sep 16, 2022 | A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer NCT03558503 · Bladder Cancer, Urothelial Carcinoma UGN-102 | URGN UroGen Pharma Ltd. | Phase 2 | Completed | 63 | Jan 3, 2020 | Registry ↗ |
| Dec 22, 2020 | The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study NCT02793128 · Carcinoma, Transitional Cell, Transitional Cell Carcinoma o… UGN-101 instillations | URGN UroGen Pharma Ltd. | Phase 3 | Completed | 71 | Apr 5, 2019 | Registry ↗ |
| May 7, 2020 | Efficacy and Safety of UGN-101 in Recurrent Patients NCT04006691 · Carcinoma, Transitional Cell Carcinoma UGN-101 instillations | URGN UroGen Pharma Ltd. | Phase 3 | Withdrawn | 0 | Mar 31, 2020 | Registry ↗ |
| Jun 16, 2017 | Safety and Efficacy Study of Intravesical Instillations of BotuGelTM, Slow Release RTGel Based Boto… NCT02674269 · Overactive Bladder 300 IU of BotuGelTM (60ml), 400 IU of BotuGelTM (60ml) | URGN UroGen Pharma Ltd. | Phase 1/2 | Withdrawn | 0 | Oct 2016 | Registry ↗ |
| Jun 16, 2017 | Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel and MMC in NMIBC Pati… NCT02307487 · Bladder Cancer, Neoplasms 120 mg MMC in 90ml gel, 140 mg MMC in 90ml gel | URGN UroGen Pharma Ltd. | Phase 2 | Completed | 14 | Apr 2016 | Registry ↗ |
| Jun 16, 2017 | Pre-TURBT TC-3 Gel Intravesical Instillation in NMIBC NCT01803295 · Carcinoma of Urinary Bladder, Superficial 40 mg MMC gel, Standard of care MMC mixed with water | URGN UroGen Pharma Ltd. | Not applicable | Completed | 80 | Jul 2016 | Registry ↗ |
| Sep 8, 2016 | Pilot Study to Evaluate the Clinical Response to Mitomycin-C in Hydrogel (TC-3) Administered Intrav… NCT02891460 · Urinary Bladder Neoplasms, Urologic Neoplasms 40 mg MMC in 40 mL TC-3., 80 mg MMC in 40 mL TC-3. | URGN UroGen Pharma Ltd. | Not applicable | Completed | 18 | Feb 2014 | Registry ↗ |
| Apr 12, 2016 | Efficacy and Safety of Intravesical Instillations of Botulinum Toxin in TC-3 Gel in IC Patients NCT01997983 · Interstitial Cystitis, IC TC-3 Gel mixed with Botox (BTX) | URGN UroGen Pharma Ltd. | Phase 1/2 | Completed | 15 | Apr 2014 | Registry ↗ |
| Mar 1, 2016 | Safety and Efficacy of Intravesical Botulinum Toxin in TC-3 Gel in OAB Patients NCT02179099 · Overactive Bladder BTX mixed with TC-3 Gel | URGN UroGen Pharma Ltd. | Phase 1/2 | Terminated | 3 | Nov 2015 | Registry ↗ |
| Sep 1, 2015 | A Prospective Open Label Comparative Dose Ranging Study Evaluating the Effect of Pre-TURBT Intraves… NCT01799499 · Non Muscle Invasive Bladder Cancer TC-3 hydrogel, TC-3 hydrogel | URGN UroGen Pharma Ltd. | Not applicable | Withdrawn | 0 | Mar 2013 | Registry ↗ |
18 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 8:20 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances